Express Pharma
Home  »  Latest Updates  »  Aurobindo inks pact with Advent Pharmaceuticals for $12.5 million

Aurobindo inks pact with Advent Pharmaceuticals for $12.5 million

72
Read Article

To acquire Australian pharma firm’s product

Aurobindo Pharma said it’s wholly-owned subsidiary has entered into an agreement to acquire a product under development and related assets from Australia-based Advent Pharmaceuticals for $12.5 million.

“Our wholly-owned subsidiary, Aurobindo Pharma USA, USA, has entered into an agreement to acquire a product under development and related assets from Advent Pharmaceuticals, Australia, through AuroScience, Melbourne, a 100 per cent subsidiary of Aurobindo Pharma USA Inc, USA,” a regulatory filing from Aurobindo said.

Based out of Melbourne, Advent Pharmaceuticals is engaged in developing and commercialising generic inhaled medicines for global markets.

Comments are closed.

Smart Pharma Packaging Technologies. Attend webinar & learn how to ensure the safety & efficacy of medicines.
Register Now
close-image